Literature DB >> 35689675

Dexamethasone prescribing for cancer pain between palliative care and radiation oncology.

Andrew Jeong1, Kevin Wade2.   

Abstract

PURPOSE: Dexamethasone is a commonly prescribed corticosteroid by both palliative care physicians and radiation oncologists for the treatment of metastatic cancer pain. However, clinical evidence for dexamethasone dose and efficacy is lacking, and prescribing between these different specialties may be influenced by other factors. This study investigates the dexamethasone prescriptions of palliative care physicians and radiation oncologists for cancer pain and their prescription rationales.
METHODS: Palliative care physicians and radiation oncologists in British Columbia, Canada, were surveyed on their preferred dexamethasone prescription in response to 4 case vignettes of patients with metastatic cancer and asked to choose a rationale from a list of options which were then categorized as "habit-based," "results-based," or "evidence-based." Response frequencies between the specialties were compared with odds ratios.
RESULTS: The total daily dose and duration of dexamethasone prescriptions were similar between the specialties. Palliative care physicians were significantly more likely than radiation oncologists to prescribe a single daily dose of dexamethasone rather than a divided dose (OR 3.3 [95% CI 2.0-5.5]). This significant difference persisted when separately analyzing results at different total daily doses. Both specialties were more likely to select habit-based rationales rather than evidence-based rationales, with no significant difference between specialties.
CONCLUSION: These findings show that dexamethasone prescriptions are habit-based and that prescribing habits are different between palliative care physicians and radiation oncologists. Interventions based on these findings could potentially prevent unequal patient care. Further qualitative investigations of physician perceptions are indicated to better understand habit-based corticosteroid prescribing patterns.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cancer pain; Corticosteroids; Dexamethasone; Palliative care; Prescribing; Radiation oncology

Mesh:

Substances:

Year:  2022        PMID: 35689675     DOI: 10.1007/s00520-022-07203-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.359


  27 in total

1.  A retrospective observation of corticosteroid use at the end of life in a hospice.

Authors:  Craig Gannon; Penny McNamara
Journal:  J Pain Symptom Manage       Date:  2002-09       Impact factor: 3.612

2.  Corticosteroid therapy of preterminal gastrointestinal cancer.

Authors:  C G Moertel; A J Schutt; R J Reitemeier; R G Hahn
Journal:  Cancer       Date:  1974-06       Impact factor: 6.860

3.  Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic.

Authors:  Sriram Yennurajalingam; Diana L Urbauer; Katie L B Casper; Cielito C Reyes-Gibby; Ray Chacko; Valerie Poulter; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2010-08-24       Impact factor: 3.612

4.  The use of corticosteroids in Swedish palliative care.

Authors:  Staffan H Lundström; Carl Johan Fürst
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

5.  A prospective survey of the use of dexamethasone on a palliative care unit.

Authors:  J R Hardy; E Rees; J Ling; R Burman; D Feuer; K Broadley; P Stone
Journal:  Palliat Med       Date:  2001-01       Impact factor: 4.762

6.  Steroids as pain relief adjuvants.

Authors:  Melissa Vyvey
Journal:  Can Fam Physician       Date:  2010-12       Impact factor: 3.275

7.  Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial.

Authors:  Eduardo Bruera; Jario Ricardo Moyano; Raul Sala; Maria Antonieta Rico; Snezanna Bosnjak; Mariela Bertolino; Jie Willey; Florian Strasser; J Lynn Palmer
Journal:  J Pain Symptom Manage       Date:  2004-10       Impact factor: 3.612

8.  Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.

Authors:  E Bruera; E Roca; L Cedaro; S Carraro; R Chacon
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

9.  Drugs in palliative care: results from a representative survey in Germany.

Authors:  Friedemann Nauck; Christoph Ostgathe; Eberhard Klaschik; Claudia Bausewein; Martin Fuchs; Gabriele Lindena; Karl Neuwöhner; Dieter Schulenberg; Lukas Radbruch
Journal:  Palliat Med       Date:  2004-03       Impact factor: 4.762

10.  A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients.

Authors:  Sebastiano L Mercadante; Michela Berchovich; Alessandra Casuccio; Fabio Fulfaro; Salvatore Mangione
Journal:  Am J Hosp Palliat Care       Date:  2007 Feb-Mar       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.